DOWNLOAD an AIP ATTACK PLAN
template for your patients to fill out with key action steps and contact information
Calls are available in English and Spanish. Translation services can be utilized for other languages.
*These services are provided at no additional cost to your patients by Recordati Rare Diseases to help them manage their PANHEMATIN therapy. Information provided by the PL program is for educational purposes only and is not intended to replace the advice of patients' healthcare providers.
To get started, your patients can complete the program enrollment opt-in form:
Living with AIP can be challenging, but having a plan in place will allow your patients to focus on getting the care they need when they have an AIP attack.
The American Porphyria Foundation educates physicians and the general public, raises funds for research, and advocates for better policy and patient care.VISIT SITE
The Porphyrias Consortium, part of the Rare Diseases Clinical Research Network founded by the NIH, benefits patients and physicians by enabling a large-scale collaborative effort to develop new strategies and methods for diagnosis, treatment, and prevention of illness and disability resulting from these rare disorders.VISIT SITE
The National Organization for Rare Diseases (NORD) is a federation of voluntary health organizations dedicated to helping people with rare “orphan” diseases.VISIT SITE
The United Porphyrias Association is committed to improving the quality of life of people with porphyria and focuses on advancing disease awareness, research, and therapies.VISIT SITE
PANHEMATIN® is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.
Limitations of Use
Indications And UsagePANHEMATIN® is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.
You are about to leave the PANHEMATIN.com website and enter a website operated by an independent third party. The links to third-party websites contained on PANHEMATIN.com are provided solely for your convenience. Recordati Rare Diseases does not control the opinions, claims or comments contained on any third-party website linked to PANHEMATIN.com, and your activities at those websites will be governed by the policies and practices of those third parties.